Holen Sie sich die Stockscreener-App
1.09
2.68%
-0.03
Xortx Therapeutics Inc Aktie (XRTX) Neueste Nachrichten
XORTX appoints finance veteran as its new CFO - MSN
XORTX Therapeutics Welcomes New CFO Dr. Bumby - TipRanks
XORTX Strengthens Executive Team - GlobeNewswire
XORTX Therapeutics Taps Former Eli Lilly Veteran Dr. Michael Bumby as New CFO - StockTitan
XORTX Therapeutics Unveils New Kidney Disease Discoveries - TipRanks
XORTX Announces Presentation at the Rare and Genetic Disease Summit - GlobeNewswire
XORTX Therapeutics Unveils Breakthrough ADPKD Research: Genetic Factors Key to Disease Progression - StockTitan
XORTX Therapeutics Inc. Faces Financial Challenges - TipRanks
XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 - sharewise
XORTX Highlights Kidney Disease Study at ASN - TipRanks
XORTX Secures $1.5 Million in Latest Offering - TipRanks
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
XORTX Therapeutics stock falls after pricing $1.5M capital raise - MSN
XORTX Therapeutics Announces $1.5 Million Offering - TipRanks
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
The Significance of Moving Averages in XORTX Therapeutics Inc Inc. (XRTX) Price Performance - The InvestChronicle
XORTX Therapeutics Advances Precision Kidney Care - TipRanks
XORTX Initiates Precision Medicine Program - GlobeNewswire
XORTX Therapeutics Inc. Initiates Precision Medicine Program - Marketscreener.com
S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
XORTX Therapeutics (NASDAQ:XRTX) Stock Quotes, Forecast and News Summary - Benzinga
SEC Form 424B3 filed by XORTX Therapeutics Inc. - Quantisnow
Form 424B3 XORTX Therapeutics Inc. - StreetInsider.com
XORTX Therapeutics Shareholders Approve Key Decisions - TipRanks
XORTX Announces Results of Annual and Special Meeting of Shareholders - GlobeNewswire
XORTX Announces Results of Annual and Special Meeting of Shareholders | XRTX Stock News - StockTitan
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A - GlobeNewswire
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Ford Motor Company (F-N) QuotePress Release - The Globe and Mail
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
XORTX Prepares for Shareholders’ Vote on Key Resolutions - TipRanks
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders - GlobeNewswire
In the Green: XORTX Therapeutics Inc (XRTX) Closes at 2.38, Up/Down 7.69 from Previous Day - The Dwinnex
Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal
Views of Wall Street’s Leading Experts on XORTX Therapeutics Inc - SETE News
XORTX Recommended by ISS for Shareholder Approval - TipRanks
XORTX Therapeutics Inc (XRTX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Independent Proxy Advisory Firm ISS Recommends XORTX - GlobeNewswire
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders - Yahoo Finance
Immersion Corp (NASDAQ: IMMR): An Enticing Stock To Watch - Stocks Register
Comstock Inc (AMEX: LODE) Has Great Upside Potential - Stocks Register
Value of company developing kidney disease treatments doubles in one day - Kursiv Media
Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.59% - MSN
XORTX Therapeutics Inc Inc. (XRTX) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Wall Street-Heavily Traded - WDRB
XORTX Therapeutics Gain 87% Following Publication of Research Supporting Treatment Pipeline - MarketWatch
XORTX Therapeutics (XRTX) Stock Up On Major Research Development - Stocks Telegraph
BioCardia Inc (Nasdaq: BCDA) Achieves Significant FDA Clearance for Morph DNA Steerable Introducer, Paving New Pathways in Cardiovascular Interventions - BP Journal
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal
Nasdaq Surges Over 1%; Best Buy Posts Upbeat Earnings - Benzinga
XORTX’s Research Reinforces Kidney Disease Treatment Strategy - TipRanks
XRTX’s valuation metrics: A comprehensive analysis - US Post News
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):